Table 3.

Clinical characteristics of THSD7A-Ab–positive patients with MN and malignancy

Patient	Sex, Age, yr	Tumor	Tumor Treatment	Specific Treatment of MN	Time of Diagnosis of Tumor	At the Time of MN Diagnosis			End Point	Follow-Up Time, mo
						Prot	S-Crea, mg/dl	THSD7A-Ab Level
1	W, 39	Gall bladder carcinoma	Palliative surgery and chemotherapy	No	1 mo after MN	4.0 g/g creatinine	0.5	1:100	S-Crea: 0.7 mg/dl; Prot: 0.2 g/g creatinine; THSD7A-Ab: neg	15
2	M, 43	Gastrointestinal stroma tumor	Surgery, curative	CsA and Pred	3 mo after MN	10.7 g/d	1.0	1:1000	S-Crea: 1.4 mg/dl; Prot: 1.8 g/d; THSD7A-Ab: 1:320	45
3	W, 76	Gynecologic tumor, not further specified	Palliative	na	na	na	na	1:1000	na	na
4	M, 65	Prostate carcinoma	Palliative	CsA, CYC, and Pred	19 mo after MN diagnosis	8.2 g/d	0.8	1:1000	Patient deceased because of the tumor	20
5	M, 53	MALT lymphoma	Surgery, radiation	No	Relapse at the time of MN diagnosis; first diagnosis of lymphoma 2 yr earlier	4.0 g/g creatinine	1.1	1:3200	S-Crea: 1.1 mg/dl; Prot: na; THSD7A-Ab: neg	14
6	M, 74	Colon carcinoma	Endoscopy, curative	CYC and Pred	4 mo after MN diagnosis	10.9 g/g creatinine	3.0	1:1000	S-Crea: 2.5 mg/dl; Prot: 0.1 g/g creatinine; THSD7A-Ab: neg	24
7	W, 77	Endometrium carcinoma	Surgery, curative	No	Relapse at the time of MN diagnosis; first diagnosis of carcinoma 17 yr earlier	4.6 g/d	0.8	THSD7A-Ab: neg; enhanced glomerular THSD7A staining	S-Crea: 0.9 mg/dl; Prot: 1.8 g/d; THSD7A-Ab: neg	9
8	M, 77	Prostate carcinoma	Androgen deprivation therapy; palliative radiation therapy	No	22 mo before MN diagnosis	7.0 g/g creatinine; 11.7 g/d	1.47	1:100	Patient deceased because of the tumor	38

Prot, proteinuria; S-Crea, serum creatinine; W, woman; neg, negative; M, man; CsA, cyclosporin A; Pred, prednisone; na, not applicable; CYC, cyclophosphamide; MALT, mucosa associated lymphoid tissue.